Discussion
cancer, tumour, CRC
CANCER, TUMOUR, ADENOCARCINOMA, GASTRIC CANCER
Paclitaxel plus RAM is established as a standard treatment of second-line treatment for advanced GC according to the result of RAINBOW trial [The therapeutic development of FTD/TPI plus anti-angiogenic drugs is more advanced for CRC than for gastric cancer. Preclinical studies have reported that the combination of FTD/TPI and bevacizumab further suppressed tumour growth compared to FTD/TPI monotherapy in xenograft models of CRC cells [Recently, nivolumab combined with chemotherapy in the first-line setting recently showed significant superiority to chemotherapy alone in both OS and PFS in advanced GC patients according to the result of the CheckMate 649 trial [There are other candidates for the combination chemotherapy in the third-line chemotherapy for patients with advanced GC and EGJ adenocarcinoma. Mizukami et al. recently reported the clinical outcomes of a phase I trial of FTD/TPI plus irinotecan for third- or later- line treatment for GC patients [Recently, INTEGRATE IIa, a randomised phase III study of regorafenib versus placebo in refractory advanced GC or EGJ cancer showed that regorafenib significantly improved OS compared with placebo [